Compared with the placebo group, the CagriSema group more often achieved weight loss of 5%, 20%, 25% and 30% at 68 weeks (P < .001 for all), Garvey and colleagues found.

In comparison, the average weight loss in the phase 3 clinical trials was 14.9% for once-weekly semaglutide 2.4 mg, 15.0% for tirzepatide 5 mg, and 20.9% for tirzepatide 15 mg.

Weight loss therapeutics is a lucrative market and one that has now landed Novo Nordisk DKK65.1 billion, or more than US$10 billion, in profits – with nearly half of this from 2024 alone.